摘要
目的 分析阿昔洛韦与静注人免疫球蛋白在病毒性脑炎患者中的应用效果。方法 选择新郑市人民医院2018年2月至2020年2月收治的病毒性脑炎患者122例,按照随机数字表法分为观察组(N=61)、对照组(N=61)。对照组予以阿昔洛韦治疗,观察组予以阿昔洛韦联合人免疫球蛋白静注治疗,比较两组症状恢复时间,血清、脑脊液炎症因子,血清、脑脊液免疫细胞表达水平,生活质量及不良反应发生率。结果 观察组症状恢复时间均短于对照组,差异有统计学意义(P<0.05)。治疗后两组血清、脑脊液炎症因子INF-γ、IL-6、TNF-α及PCT水平低于治疗前,且观察组炎症因子水平明显低于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清、脑脊液CD8+免疫细胞表达水平降低,CD3+、CD4+及CD4+/CD8+的表达水平增高,且观察组血清、脑脊液CD8+免疫细胞表达水平低于对照组,CD3+、CD4+及CD4+/CD8+的表达水平均高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组生活质量优于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率(6.56%)高于对照组(4.92%),但组间不良反应发生率比较差异无统计学意义(P>0.05)。结论 人免疫球蛋白能够有效改善病毒性脑炎患者的免疫细胞水平、降低其炎症因子水平,提升患者生活质量,联合用药后患者并未明显增加不良反应,证实阿昔洛韦与静注人免疫球蛋白在病毒性脑炎患者中的临床治疗安全性好且疗效尚佳。
Objective To analyze the effect of acyclovir and intravenous human immunoglobulin in patients with viral encephalitis.Methods A total of 122 patients with viral encephalitis admitted to Xinzheng People’s Hospital from February 2018to February 2020 were randomly divided into observation group(N=61)and control group(N=61).The control group was treated with acyclovir,and the observation group was treated with acyclovir combined with human immunoglobulin intravenously.The recovery time of symptoms,serum infiammatory factors,cerebrospinal fiuid infiammatory factors,expression level of serum and cerebrospinal fiuid immune cells,quality of life,and incidence of adverse reactions were compared between the two groups.Results The recovery time of the observation group was shorter than the control group,with significant difference(P<0.05);After treatment,the levels of serum,cerebrospinal fiuid infiammatory factors INF-γ,IL-6,TNF-αand PCT in the two groups were lower than those before treatment,and the levels of infiammatory factors in the observation group were significantly lower than those of the control group,showing statistically significant differences(P<0.05).After treatment,the expression level of serum and CSF CD8^(+)immune cells decreased,the expression levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)increased,moreover,the expression level of serum and CSF CD8^(+)immune cells in the observation group were lower than those in the control group,and the expression levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,which were statistically significant(P<0.05).After treatment,the quality of life of the observation group was better than the control group,with significant difference(P<0.05).The incidence of adverse reactions in the observation group(6.56%)was higher than that in the control group(4.92%),but the difference in the incidence of adverse reactions between the groups was not significant(P>0.05).Conclusion Human immunoglobulin can effectively improve
作者
刘园
王莉
LIU Yuan;WANG Li(Department of Neurology,Xinzheng People’s Hospital,Xinzheng Henan 451100,China)
出处
《临床研究》
2023年第3期58-61,共4页
Clinical Research
关键词
人免疫球蛋白
病毒性
脑炎
炎症因子
human immunoglobulin
viral
encephalitis
infiammatory factors
